Surgery versus radical endotherapies for early cancer and high-grade dysplasia in Barrett's oesophagus

Cochrane Database of Systematic Reviews

Volumn 2020, Issue 5, 2020, Pages

  Bennett, Cathy ^a   Green, Susi ^b   DeCaestecker, John ^c   Almond, Max ^d   Barr, Hugh ^d   Bhandari, Pradeep ^b   Ragunath, Krish ^e   Singh, Rajvinder ^f   Jankowski, Janusz ^g  

^a Faculty of Engineering and Computing   (United Kingdom)

^b PORTSMOUTH HOSPITALS NHS TRUST   (United Kingdom)

^c UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^d GLOUCESTERSHIRE ROYAL HOSPITAL   (United Kingdom)

^e QUEEN S MEDICAL CENTRE   (United Kingdom)

^f LYELL MCEWIN HOSPITAL   (Australia)

^g QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BARRETT ESOPHAGUS; ESOPHAGOSCOPY; ESOPHAGUS TUMOR; HUMAN; PATHOLOGY; PRECANCER; PROCEDURES; METHODOLOGY; REVIEW;

BARRETT ESOPHAGUS; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; HUMANS; PRECANCEROUS CONDITIONS;

EID: 77953628814     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007334.pub5     Document Type: Review

References (123)

1. Das A, Singh A, Fleischer D, Sharma V. A comparison of endoscopic treatment and surgery in early esophageal cancer: an analysis of surveillance epidemiology and end results data. American Journal of Gastroenterology 2008;103:1340-5. x-wiley/crsRef/3017011
2. Farrell NO, Ravi N, Malik V, Larkin JO, Wilson GF, Muldoon C, et al. Evolving changes in the management of early oesophageal adenocarcinoma. Irish Journal of Medical Science.Conference: 36th Sir Peter Freyer Memorial Lecture and Surgical Symposium Galway Ireland. Conference 2011 Sept 2 to 2011 Sept 3 2011:S253. x-wiley/crsRef/3017013 [0021-1265]
3. Pacifico RJ, Wang KK, Wongkeesong L, Buttar NS, Lutzke LS. Combined endoscopic mucosal resection and photodynamic therapy versus esophagectomy of early adenocarcinoma in Barrett's esophagus. Clinical Gastroenterology and Hepatology 2003;1:252-7. x-wiley/crsRef/3017015
4. Leung WD, Chennat J. Comparison of endoscopic and surgical resection of intramucosal carcinoma in Barretts esophagus. Expert Review of Gastroenterology and Hepatology 2011;5(5):575-8. x-wiley/crsRef/3017017 [1747-4124]
5. Pech O, Bollschweiler E, Manner H, Leers J, Ell C, Holscher AH. Comparison between endoscopic and surgical resection of mucosal esophageal adenocarcinoma in Barrett's esophagus at two high-volume centers. Annals of Surgery 2011;254(1):67-72. x-wiley/crsRef/3017018 [0003-4932]
6. Prasad G, Wang K, Buttar N, Wongkeesong L, Krishnadath K, Nichols F, et al. Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus. Gastroenterology 2007;132:1226-33. x-wiley/crsRef/3017020
7. Reed MF, Tolis G, Edil BH, Allan JS, Donahue DM, Gaissert HA, et al. Surgical treatment of esophageal high-grade dysplasia. Annals of Thoracic Surgery 2005;79:1110-5. x-wiley/crsRef/3017022
8. Rosmolen WD, Boer KR, De Leeuw RJR, Gamel CJ, Van BH, Bergman JJGH. Quality of life and fear of cancer recurrence after endoscopic and surgical treatment for early neoplasia in Barretts esophagus. Endoscopy 2010;42(7):525-31. x-wiley/crsRef/3017024 [0013-726X]
9. Schembre D, Huang J, Lin O, Cantone N, Low D. Treatment of Barrett's esophagus with early neoplasia: a comparison of endoscopic therapy and esophagectomy. Clinical Endoscopy 2008;67(4):595-601. x-wiley/crsRef/3017026
10. Schembre D, Arai A, Levy S, Farrell-Ross M, Low D. Quality of life after esophagectomy and endoscopic therapy for Barrett's esophagus with dysplasia. Diseases of the Esophagus 2010;23(6):458-64. x-wiley/crsRef/3017028 [1120-8694]
11. Thomas T, Richards CJ, de Caestecker JS, Robinson RJ. High-grade dysplasia in Barrett's oesophagus: natural history and review of clinical practice. Alimentary Pharmacology and Therapeutics 2005;21(6):747-55. x-wiley/crsRef/3017030 [PMID: 15771761]
12. Tian J, Prasad GA, Lutzke LS, Lewis JT, Wang KK. Outcomes of T1b esophageal adenocarcinoma patients. Gastrointestinal Endoscopy 2011;74(6):1201-6. x-wiley/crsRef/3017032 [0016-5107]
13. Yachimski P, Nishioka NS, Richards E, Hur C. Treatment of Barrett's esophagus with high-grade dysplasia or cancer: predictors of surgical versus endoscopic therapy. Clinical Gastroenterology and Hepatology 2008;6(11):1206-11. x-wiley/crsRef/3017034
14. Zehetner J, DeMeester SR, Hagen JA, Ayazi S, Augustin F, Lipham JC, et al. Endoscopic resection and ablation versus esophagectomy for high-grade dysplasia and intramucosal adenocarcinoma. Journal of Thoracic and Cardiovascular Surgery 2011;141(1):39-47. x-wiley/crsRef/3017036 [0022-5223]
15. DeCaestecker J, Ragunath K, Smart H, Barr H, Lovat L Bhandari P. BRIDE [Trial not yet registered; funded by RfPB (PB-PG-0711-25066)]. start date 4/2/2013 2012. x-wiley/crsRef/3017038
16. Akiyama H, Tsurumaru M, Kawamura T, Ono Y. Esophageal stripping with preservation of the vagus nerve. International Surgery 1982;2:125-8.
17. Alvarez Herrero L, Pouw RE, van Vilsteren FG, ten Kate FJW, Visser M, van Berge Henegouwen, et al. Risk of lymph node metastasis associated with deeper invasion by early adenocarcinoma of the esophagus and cardia: study based on endoscopic resection specimens. Endoscopy 2010;42(12):1030-6.
18. Attwood S, Lewis C, Caplin S, Hemming K, Armstrong G. Argon beam photocoagulation as therapy for high grade dysplasia in Barrett's esophagus. Clinical Gastroenterology and Hepatology 2003;1(4):258-63.
19. Auger CP. Information Sources in Grey Literature. 4th edition. London: Bowker-Saur, 1998.
20. Banki F, Mason RJ, Hagen JA, Balaji NS, Crookes PF, Bremner CG, et al. Vagal-sparing esophagectomy: a more physiologic alternative. Annals of Surgery 2002;236(3):324-36.
21. Basu KK, Pick B, de Caestecker JS. Audit of a Barrett's epithelium surveillance database. European Journal of Gastroenterology and Hepatology 2004;16:1-5.
22. Bennett C, Vakil N, Bergman J, Harrison R, Odze R, Vieth M, et al. Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a delphi process. Gastroenterology 2012;143(2):336-46. [PMID: 22537613]
23. Bhat S, Coleman HG, Yousef F, Johnston BT, McManus DT, Gavin AT, et al. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. Journal of the National Cancer Institute 2011;103(13):1049-57.
24. Biddlestone LR, Barham CP, Wilkinson SP, Barr H, Shepherd NA. The histopathology of treated Barrett's oesophagus: squamous re-epithelialisation following acid suppression, laser and photodynamic therapy. American Journal of Surgical Pathology 1998;22(2):239-45.
25. Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, Wennberg DE, et al. Hospital volume and surgical mortality in the United States. New England Journal of Medicine 2002;346(15):1128-37.
26. Blazeby J. Medicinal herbs for esophageal cancer [comment]. Cochrane Database of Systematic Reviews 2007. [DOI: 10.1002/14651858.CD004520.pub3]
27. Boger PC, Turner D, Roderick P, Patel P. A UK-based cost-utility analysis of radiofrequency ablation or oesophagectomy for the management of high-grade dysplasia in Barrett's oesophagus. Alimentary Pharmacology & Therapeutics 2010;32(11-12):1332-42.
28. Bronner MP, Overholt BF, Taylor SL, Haggitt R, Wang K, Burdick JS, et al. Squamous overgrowth is not a safety concern for photodynamic therapy for Barrett's esophagus with high-grade dysplasia. Gastroenterology 2009;136(1):56-64.
29. Brown LM, Swanson CA, Gridley G, Swanson GM, Silverman DT, Greenberg RS, et al. Dietary factors and the risk of squamous cell esophageal cancer among black and white men in the United States. Cancer Causes and Control 1998;9(5):467-74.
30. Buttar NS, Wang KK, Sebo TJ, Riehle DM, Krishnadath KK, Lutzke LS, et al. Extent of high grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 2001;120:1630-9.
31. Byrne JP, Mathers JM, Parry JM, Attwood SEA, Bancewicz J, Woodman CBJ. Site distribution of oesophageal cancer. Journal of Clinical Pathology 2002;55:191-4.
32. Caldwell MT, Lawlor P, Byrne PJ, Walsh TN, Hennessy TP. Ambulatory oesophageal bile reflux monitoring in Barretts oesophagus. British Journal of Surgery 1995;82:657-60.
33. Cameron AJ, Zinsmeister AR, Ballard DJ, Carney JA. Prevalence of columnar-lined (Barrett's) oesophagus. Comparison of population based clinical and autopsy findings. Gastroenterology 1990;99(4):918-22.
34. Chak A, Lee T, Kinnard M, Brock W, Faulx A, Willis J, et al. Familial aggregation of Barrett's oesophagus, oesophageal adenocarcinoma, and oesophagogastric junctional adenocarcinoma in Caucasian adults. Gut 2002;51(3):323-8.
35. Chang AC, Burkmeyer JD. The volume-performance relationship in esophagectomy. Thoracic Surgery Clinics 2006;16:87-91.
36. Chen ZM, Xu Z, Collins R, Li W-X, Peto R. Early health effects of the emerging tobacco epidemic in China: a 16-year prospective study. Journal of the American Medical Association 1997;278:1500-4.
37. Comay D, Blackhouse G, Goeree R, Armstrong D, Marshall JK. Photodynamic therapy for Barrett's esophagus with high-grade dysplasia: a cost-effectiveness analysis. Canadian Journal of Gastroenterology 2007;21(4):217-22. [PMID: 17431509]
38. Corley DA, Kubo A, Levin TR, Block G, Habel L, Zhao W, et al. Abdominal obesity and body mass index as risk factors for Barrett's esophagus. Gastroenterology 2007;133:34-41.
39. Cancer Research UK. UK Oesophageal cancer incidence statistics. info.cancerresearchuk.org/cancerstats/types/oesophagus/incidence/uk-oesophageal-cancer-incidence-statistics#Anatomy (accessed 17 May 2012).
40. Curvers WL, Ten Kate FJ, Krishnadath KK, Visser M, Elzer B, Baak LC, et al. Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. American Journal of Gastroenterology 2010;105(7):1523-30. [0002-9270]
41. de Vries DR, ter Linde JJM, van Herwaarden MA, Smout AJPM, Samsom M. Gastroesophageal reflux disease is associated with the C825T polymorphism in the g-protein 3 subunit gene (GNB3). American Journal of Gastroenterology 2009;104:281-5.
42. DeMeester SR. New options for the therapy of Barrett's high-grade dysplasia and intramucosal adenocarcinoma: endoscopic mucosal resection and ablation versus vagal spearing esophagectomy. Annals of Thoracic Surgery 2008;85:S747-90.
43. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-88.
44. Edelstein ZR, Farrow DC, Bronner MP, Rosen SN, Vaughan TL. Central adiposity and risk of Barrett's esophagus. Gastroenterology 2007;133(2):403-11.
45. Efficace F, Bottomley A, Osoba D, Gotay C, Flechtner H, D'haese S, et al. Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials - does HRQOL evaluation in prostate cancer research inform clinical decision making? Journal of Clinical Oncology 2003;18:3502-11.
46. Ell C, May A, Pech O, Gossner L, Guenter E, Behrens A, et al. Curative endoscopic resection of early esophageal adenocarcinomas (Barrett's cancer). Clinical Endoscopy 2007;65(1):3-10.
47. Engel LS, Chow WH, Vaughan TL, Gammon MD, Risch HA, Stanford LM, et al. Population attributable risks of esophageal and gastric cancers. Journal of the National Cancer Institute 2003;95:1404.
48. Giovannini M, Bories E, Pesenti C, Mountardier V, Monges G, Danisi C, et al. Circumferectial endoscopic mucosal resection in Barrett's esophagus with high-grade intraepithelial neoplasia or mucosal cancer, preliminary results in 21 patients. Endoscopy 2004;36(9):782-7.
49. Gondrie JJ, Pouw RE, Sondermeijer CM, Peters FP, Curvers WL, Rosmolen WD, et al. Stepwise circumferential and focal ablation of Barrett's esophagus with high-grade dysplasia: results of the first prospective series of 11 patients. Endoscopy 2008;40(5):359-69.
50. Gondrie JJ, Pouw RE, Sondermeijer CM, Peters FP, Curvers WL, Rosmolen WD, et al. Effective treatment of early Barrett's neoplasia with stepwise circumferential and focal ablation using the HALO system. Endoscopy 2008;40(5):370-9.
51. Green S, Bhandari P, DeCaestecker J, Barr H, Ragunath K, Jankowski J, et al. Endoscopic therapies for the prevention and treatment of early esophageal neoplasia. Expert Review of Gastroenterology and Hepatology 2011;5(6):731-43. [PMID: 22017700]
52. Greenstein A, Wisnivesky J, Litle V. Effect of local therapy for the treatment of superficial esophageal cancer in non-operative candidates. Diseases of the Esophagus 2008;21(8):673-8. [DOI: 10.111/j.1442-2050.2008.00832]
53. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Annals of Internal Medicine 2005;143(3):199-211.
54. Hellier MD, Sanderson JD, Morris AI, Elias E, De Caestecker J. Care of patients with gastrointestinal disorders in the United Kingdom: a strategy for the future, 2006. www.bsg.org.uk/pdf_word_docs/strategy06_final.pdf. http://(accessed 8 October 2012).
55. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
56. Holscher AH, Bollschweiler E, Schneider PM, Siewert JR. Early adenocarcinoma in Barrett's oesophagus. British Journal of Surgery 1997;84:1470-3.
57. Hornick JL, Blount PL, Sanchez CA, Cowan DS, Ayub KM, Maley CC, et al. Biological properties of columnar epithelium underneath reepithelialized squamous mucosa in Barrett's esophagus. American Journal of Surgical Pathology 2005;29:372-80.
58. Hornick JL, Mino-Kenudson M, Lauwers GY, Liu W, Goyal R, Odze RD. Buried Barrett's epithelium following photodynamic therapy shows reduced crypt proliferation and absence of DNA content abnormalities. American Journal of Gastroenterology 2007;103(1):38-47.
59. Hulscher F, van Sandick J, de Boer A, Wijnhoven B, Tijssen J, Fockens P. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. New England Journal of Medicine 2002;347:1662-9.
60. Hung HC, Huang MC, Lee JM, Wu DC, Hsu HK, Wu MT. Association between diet and esophageal cancer in Taiwan. Journal of Gastroenterology and Hepatology 2004;19(6):632-7.
61. Hur C, Nishioka NS, Gazelle GS. Cost-effectiveness of photodynamic therapy for treatment of Barrett's esophagus with high grade dysplasia. Digestive Diseases and Sciences 2003;48:1273-83.
62. Hvid-Jensen F, Pedersen L, Drewes AM, Sroensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett's esophagus. New England Journal of Medicine 2011;365(15):1375-83. [0028-4793]
63. Inadomi J, Somsouk M, Thomas J, Shaheen N. A cost-utility analysis of ablative therapy for Barrett's esophagus. Gastroenterology 2009;136:2101-14.
64. Jamieson G, Mathew G, Ludemann R, Wayman J, Myers J, Devitt P. Postoperative mortality following oesophagectomy and problems in reporting its rate. British Journal of Surgery 2004;5:943-7.
65. Jankowski JA, Wright NA, Meltzer SJ, Triadafilopoulos G, Geboes K, Casson AG, et al. Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the oesophagus. American Journal of Pathology 1995;154:965-73.
66. Keeley SB, Pennathur A, Gooding W, Landreneau RJ, Christie NA, Luketich J. Photodynamic therapy with curative intent for Barrett's esophagus with high grade dysplasia and superficial esophageal cancer. American Journal of Surgical Oncology 2007;14(8):2406-10.
67. Kelty CJ, Gough MD, Van Wyk Q, Stephenson TJ, Ackroyd R. Barrett's oesophagus: intestinal metaplasia is not essential for cancer risk. Scandinavian Journal of Gastroenterology 2007;42(11):1271-4.
68. Konda VJ, Ross AS, Ferguson MK, Hart JA, Lin S, Naylor K, et al. Is the risk of concomitant invasive esophageal cancer in high grade dysplasia in Barrett's esophagus overestimated? Clinical and Experimental Pathology 2008;6(2):159-64.
69. Konda VJ, Waxman I. Endotherapy for Barrett's esophagus. American Journal of Gastroenterology 2012;107(6):827-33. [PMID: 22488078]
70. Lagergren J, Bergström R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux is a strong risk factor for esophageal adenocarcinoma. New England Journal of Medicine 1999;340:825-31.
71. Lagergren J, Ye W, Lindgren A, Nyrén O. Heredity and risk of cancer of the esophagus and gastric cardia. Cancer Epidemiology, Biomarkers and Prevention 2000;9:757-60.
72. Leers JM, DeMeester SR, Oezcelik A, Klipfel N, Ayazi S, Abate E, et al. The prevalence of lymph node metastases in patients with T1 esophageal adenocarcinoma a retrospective review of esophagectomy specimens. Annals of Surgery 2011;253(2):271-8. [PMID: 21119508]
73. Liu W, Hahn Hodze RD, Goyal RK. Metaplastic esophageal columnar epithelium without goblet cells shows DNA content abnormalities similar to goblet cell containing epithelium. American Journal of Gastroenterology 2009;104(4):816-24.
74. Lui L, Hofstetter W, Rashid A, Swisher S, Correa A, Ajani J, et al. Significance of the depth of tumor invasion and lymph node metastasis in superficially invasive (T1) esophageal adenocarcinoma. American Journal of Surgical Pathology 2005;29:1079-85.
75. May A, Gossner L, Pech O, Fritz A, Gunter E, Mayer G, et al. Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett's oesophagus: acute phase and intermediate results of a new treatment approach. European Journal of Gastroenterology 2002;14:1085-91.
76. Menon D, Stafinski T, Wu H, Lau D, Wong C. Endoscopic treatments for Barrett's esophagus: a systematic review of safety and effectiveness compared to esophagectomy. BMC Gastroenterology 2010;10:111.
77. Mino-Kenudson M, Ban, S, Ohana M, Puricelli W, Deshpande V, Shimizu, M et al. Buried dysplasia and early adenocarcinoma arising in Barrett esophagus after porfimer-photodynamic therapy. American Journal of Surgical Pathology 2007;31:403-9.
78. Moayyedi P, Burch N, Akhtar-Danesh N, Enaganti SK, Harrison R, Talley NJ, et al. Mortality rates in patients with Barrett's oesophagus. Alimentary Pharmacology and Therapeutics 2008;27(4):316-20.
79. Morita M, Kuwano H, Ohno S, Sugimachi K, Seo Y, Tomoda H, et al. Multiple occurrence of carcinoma in the upper aerodigestive tract associated with esophageal cancer: reference to smoking, drinking and family history. International Journal of Cancer 1994;58:207-10.
80. Moss A, Bourke MJ, Hourigan LF, Gupta S, Williams SJ, Tran K, et al. Endoscopic resection for Barrett's high-grade dysplasia and early esophageal adenocarcinoma: an essential staging procedure with long-term therapeutic benefit. American Journal of Gastroenterology 2010;(6):1276-83. [0002-9270]
81. The NHS Information Centre. The third annual report of the national oesophago-gastric audit, 2010. www.ic.nhs.uk/webfiles/Services/NCASP/audits%20and%20reports/NHS%20IC%20OGC%20Audit%202010%20interactive.pdf. (accessed 8 October 2012).
82. National Institute for Health and Clinical Excellence. Barrett's oesophagus: ablative therapy for the treatment of Barrett's oesophagus, 2010. www.nice.org.uk/guidance/CG106 (accessed 8 October 2012).
83. Overholt B, Wang K, Burdick S, Lightdale C, Kimmey M, Nava H, et al. Five-year efficacy and safety of photodynamic therapy with photofrin in Barrett's high-grade dysplasia. Clinical Endoscopy 2007;66(3):460-8.
84. Pech O, Behrens A, May A, Gossner L, Vieth M, Stolte M, et al. Curative endoscopic therapy for Barrett's early cancer and high grade dysplasia: long-term results in 304 patients. Gastrointestinal Endoscopy 2006;63(5):AB83.
85. Pech O, May A, Rabenstein T, Ell C. Endoscopic resection of early oesophageal cancer. Gut 2007;56:1625-34.
86. Pech O, Behrens A, May A, Nachbar L, Gossner L, Rabenstein T, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut 2008;57:1200-6.
87. Peters FP, Kara MA, Rosmolen WD, Ten Kate FJW, Krishnadath KK, Lanschot JJB, et al. Stepwise radical endoscopic resection is effective for complete removal of Barrett's esophagus with early neoplasia: a prospective study. American Journal of Gastroenterology 2006;101:1449-57.
88. Peters FP, Brakenhoff KP, Curvers WL. Histological evaluation of resection specimens obtained at 293 endoscopic resections in Barrett's oesophagus. Gastrointestinal Endoscopy 2008;67:604-9.
89. Pyer C, De Meester S, Rizzetto C, Bansal N, Tang A, Ayazi S, et al. Vagal sparing esophagectomy. The ideal operation for intramucosal adenocarcinoma and Barrett with high-grade dysplasia. Annals of Surgery 2007;246(4):665-74.
90. Playford RJ. New British Society of Gastroenterology (BSG) guidelines for the diagnosis and management of Barrett's oesophagus. Gut 2006;55:442-3.
91. Pohl H, Sonnenberg A, Strobel S, Eckardt A, Rosch T. Endoscopic versus surgical therapy for early cancer in Barrett's esophagus: a decision analysis. Gastrointestinal Endoscopy 2009;70(4):623-31. [PMID: 19394011]
92. Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. American Journal of Gastroenterology 2000;95(7):1669-76.
93. The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
94. Romero Y, Cameron A, Scaid D, McDonnell S, Burgart L, Hardtke C, et al. Barrett's esophagus: prevalence in symptomatic relatives. American Journal of Gastroenterology 2002;97(5):1127-32.
95. Ronikainen J, Aro P, Storskrubb T, Johansson S, Lind T, Bolling-Sternevold E, et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 2005;129:1825-31.
96. Rouvelas I, Jia C, Viklund P, Lindblad M, Lagergren J. Surgeon volume and postoperative mortality after oesophagectomy for cancer. European Journal of Surgical Oncology 2007;33(2):162-8.
97. Rösch T. BARRx for total Barrett's eradication - the new super weapon? Endoscopy 2008;40(5):393-4.
98. Sampliner R, Fennerty MB, Garewal H. Reversal of Barrett's esophagus with acid suppression and multipolar electrocoagulation. Gastrointestinal Endoscopy 1996;44:523-5.
99. Sanchez A, Reza M, Blasco JA, Callejo D. Effectiveness, safety, and cost-effectiveness of photodynamic therapy in Barrett's esophagus: a systematic review. Diseases of the Esophagus 2010;23(8):633-40. [1120-8694]
100. Schnell TG, Sontag SJ, Chejfec G, Aranha G, Metz A, O'Connell S, et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001;120:1608-19.
101. Shaheen NJ, Inadomi JM, Overholt BF, Shamra P. What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis. Gut 2004;53:1736-44.
102. Shaheen NJ, Sharma P, Overholt B, Wolfsen H, Sampliner R, Wang K, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. New England Journal of Medicine 2009;360:2277-88.
103. Shaheen NJ, Overholt BF, Sampliner RE, Wolfsen HC, Wang KK, Fleischer DE, et al. Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. Gastroenterology 2011;141(2):460-8. [0016-5085]
104. Sharma P, Falk GW, Weston AP, Reker D, Johnston M, Sampliner RE. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clinical Gastroenterology and Hepatology 2006;4(5):566-72.
105. Sharma VK, Wang KK, Overholt BF, Lightdale CJ, Fennerty MB, Dean PJ, et al. Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett's esophagus: 1-year follow-up of 100 patients. Gastrointestinal Endoscopy 2007;65(2):185-95.
106. Sharma VK, Kim HJ, Das A, Dean P, DePetris G, Fleischer DE. A prospective pilot trial of ablation of Barrett's esophagus with low-grade dysplasia using stepwise circumferential and focal ablation (HALO system). Gastrointestinal Endoscopy 2008;40(5):380-7.
107. Sharma VK, Jae Kim H, Das A, Wells CD, Nguyen CC, Fleischer DE. Circumferential and focal ablation of Barrett's esophagus containing dysplasia. American Journal of Gastroenterology 2009;104(2):310-7.
108. Sikkema M, de Jonge PJ, Steyerberg EW, Kuipers EJ. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. Clinical Gastroenterology and Hepatology 2010;8(3):235-44.
109. Singh S, Sharma P. How effective is endoscopic therapy in the treatment of patients with early esophageal cancer? Nature Clinical Practice Gastroenterology & Hepatology 2009;6(2):70-1.
110. Skacel M, Petras RE, Gramlich TL, Sigel JE, Richter JE, Goldblum JR. The diagnosis of low grade dysplasia in Barrett's esophagus and its implication for disease progression. American Journal of Gastroenterology 2000;95(12):3383-7.
111. Stein HJ, Hutter J, Feith M, von Rahden BH. Limited surgical resection and jejunal interposition for early adenocarcinoma of the distal esophagus. Seminars in Thoracic and Cardiovascular Surgery 2007;19(1):72-8.
112. Thomas P, Doddoli C, Neville P, Pons J, Lienne P, Giudicelli R, et al. Esophageal cancer resection in the elderly. European Journal of Cardiothoracic Surgery 1996;11:941-6.
113. Thun MJ, Peto R, Lopez AD, Monaco JH, Henley SJ, Heath CW Jr, et al. Alcohol consumption and mortality among middle-aged and elderly U.S. adults. New England Journal of Medicine 1997;337:1705.
114. Urba SG, Orringer MB, Turrisi A, Lannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. Journal of Clinical Oncology 2001;19:305–13.
115. Vaezi MF, Richter JE. Synergism of acid and duodenogastroesophageal reflux in complicated Barrett oesophagus. Surgery 1995;117:699-704.
116. Vij R, Triadafilopoulos G, Owens DK, Kunz P, Sanders GD. Cost-effectiveness of photodynamic therapy for high-grade dysplasia in Barrett's esophagus. Gastrointestinal Endoscopy 2004;60(5):739-56.
117. Vizcaino AP, Moreno V, Lambert R, Parkin DM. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. International Journal of Cancer 2002;99(6):860-8.
118. Wani S, Mathur S, Sharma P. How to manage a Barrett's esophagus patient with low-grade dysplasia. Clinical Gastroenterology and Hepatology 2009;1:27-32.
119. Whooley BP, Law S, Murthy SC, Alexandrou A, Wong J. Analysis of reduced death and complication rates after esophageal resection. Annals of Surgery 2001;233(3):338-44.
120. Winters C, Spurling TJ, Chobanian SJ, Curtis DJ, Esposito RL, Cotelingam JD, et al. Barrett's esophagus. A prevalent occult complication of gastroesophageal reflux disease. Gastroenterology 1987;92:118-24.
121. Wolfson H, Hemminger L, DeVault K. Recurrent Barrett's esophagus and adenocarcinoma after esophagectomy. BMC Gastroenterology 2004;4:18. [DOI: 10.1186/1471-230X-4-18]
122. Yousef F, Cardwell C, Cantwell MM, Galway K, Johnston BT, Murray L. The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis. American Journal of Epidemiology 2008;168(3):237-49.
123. Green S, Tawil A, Barr H, Bennett C, Bhandari P, DeCaestecker J, et al. Surgery versus radical endotherapies for early cancer and high grade dysplasia in Barrett's oesophagus. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD007334.pub3]